144 related articles for article (PubMed ID: 34253650)
1. A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus.
Alexander RV; Rey DS; Conklin J; Domingues V; Ahmed M; Qureshi J; Weinstein A
Lupus Sci Med; 2021 Jul; 8(1):. PubMed ID: 34253650
[TBL] [Abstract][Full Text] [Related]
2. Complement activation products vs standard ANA testing: Treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus.
O'Malley T; Xie F; Su Y; Clinton C; Zack DJ; Haechung C; Grabner M; Curtis JR
J Manag Care Spec Pharm; 2022 Sep; 28(9):1021-1032. PubMed ID: 35775579
[No Abstract] [Full Text] [Related]
3. Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus.
Ramsey-Goldman R; Alexander RV; Massarotti EM; Wallace DJ; Narain S; Arriens C; Collins CE; Saxena A; Putterman C; Kalunian KC; O'Malley T; Dervieux T; Weinstein A
Arthritis Rheumatol; 2020 Jan; 72(1):78-88. PubMed ID: 31469249
[TBL] [Abstract][Full Text] [Related]
4. A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus.
Ramsey-Goldman R; Alexander RV; Conklin J; Arriens C; Narain S; Massarotti EM; Wallace DJ; Collins CE; Saxena A; Putterman C; Brady K; Kalunian KC; Weinstein A
ACR Open Rheumatol; 2021 Feb; 3(2):116-123. PubMed ID: 33538130
[TBL] [Abstract][Full Text] [Related]
5. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
Fasano S; Pierro L; Pantano I; Iudici M; Valentini G
J Rheumatol; 2017 Jul; 44(7):1032-1038. PubMed ID: 28507183
[TBL] [Abstract][Full Text] [Related]
6. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus.
Kalunian KC; Chatham WW; Massarotti EM; Reyes-Thomas J; Harris C; Furie RA; Chitkara P; Putterman C; Gross RL; Somers EC; Kirou KA; Ramsey-Goldman R; Hsieh C; Buyon JP; Dervieux T; Weinstein A
Arthritis Rheum; 2012 Dec; 64(12):4040-7. PubMed ID: 22932861
[TBL] [Abstract][Full Text] [Related]
7. The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus.
Miyagawa I; Nakano K; Nakayamada S; Iwata S; Hanami K; Fukuyo S; Kubo S; Kawabe A; Miyazaki Y; Inoue Y; Ueno M; Ohkubo N; Fujita Y; Tanaka Y
Int J Rheum Dis; 2020 Apr; 23(4):549-558. PubMed ID: 32020727
[TBL] [Abstract][Full Text] [Related]
8. The Avise Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus.
Mossell J; Goldman JA; Barken D; Alexander RV
Open Rheumatol J; 2016; 10():71-80. PubMed ID: 27867431
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose.
Wakiya R; Kameda T; Nakashima S; Shimada H; Fahmy Mansour MM; Kato M; Miyagi T; Kadowaki N; Dobashi H
Intern Med; 2020 Sep; 59(17):2105-2112. PubMed ID: 32522920
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal Evaluation of Lipoprotein Variables in Systemic Lupus Erythematosus Reveals Adverse Changes with Disease Activity and Prednisone and More Favorable Profiles with Hydroxychloroquine Therapy.
Durcan L; Winegar DA; Connelly MA; Otvos JD; Magder LS; Petri M
J Rheumatol; 2016 Apr; 43(4):745-50. PubMed ID: 26834214
[TBL] [Abstract][Full Text] [Related]
11. Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers.
Monzavi SM; Alirezaei A; Shariati-Sarabi Z; Tavakol Afshari J; Mahmoudi M; Dormanesh B; Jahandoost F; Khoshdel AR; Etemad Rezaie A
Inflammopharmacology; 2018 Oct; 26(5):1175-1182. PubMed ID: 29987550
[TBL] [Abstract][Full Text] [Related]
12. Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis.
Mok CC; Penn HJ; Chan KL; Tse SM; Langman LJ; Jannetto PJ
Arthritis Care Res (Hoboken); 2016 Sep; 68(9):1295-302. PubMed ID: 26749299
[TBL] [Abstract][Full Text] [Related]
13. Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital.
Hosokawa Y; Oiwa H
Intern Med; 2020 Oct; 59(20):2485-2490. PubMed ID: 32641656
[TBL] [Abstract][Full Text] [Related]
14. Hydroxychloroquine in systemic lupus erythematosus (SLE).
Ponticelli C; Moroni G
Expert Opin Drug Saf; 2017 Mar; 16(3):411-419. PubMed ID: 27927040
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and Controls.
Aberle T; Bourn RL; Munroe ME; Chen H; Roberts VC; Guthridge JM; Bean K; Robertson JM; Sivils KL; Rasmussen A; Liles M; Merrill JT; Harley JB; Olsen NJ; Karp DR; James JA
Arthritis Care Res (Hoboken); 2017 Dec; 69(12):1780-1788. PubMed ID: 28118528
[TBL] [Abstract][Full Text] [Related]
16. Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE.
Wallace DJ; Alexander RV; O'Malley T; Khosroshahi A; Hojjati M; Loupasakis K; Alper J; Sherrer Y; Fondal M; Kataria R; Powell T; Ibarra C; Narain S; Massarotti E; Weinstein A; Dervieux T
Lupus Sci Med; 2019; 6(1):e000349. PubMed ID: 31592328
[TBL] [Abstract][Full Text] [Related]
17. The risk of hospitalized infection in patients with systemic lupus erythematosus treated with hydroxychloroquine.
Sakai R; Honda S; Tanaka E; Majima M; Konda N; Takada H; Harigai M
Lupus; 2020 Nov; 29(13):1712-1718. PubMed ID: 32838624
[TBL] [Abstract][Full Text] [Related]
18. Probable systemic lupus erythematosus with cell-bound complement activation products (CB-CAPS).
Lamichhane D; Weinstein A
Lupus; 2016 Aug; 25(9):1050-3. PubMed ID: 26911153
[TBL] [Abstract][Full Text] [Related]
19. Hydroxychloroquine Inhibits the Differentiation of Th17 Cells in Systemic Lupus Erythematosus.
Yang J; Yang X; Yang J; Li M
J Rheumatol; 2018 Jun; 45(6):818-826. PubMed ID: 29545450
[TBL] [Abstract][Full Text] [Related]
20. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus.
Akhavan PS; Su J; Lou W; Gladman DD; Urowitz MB; Fortin PR
J Rheumatol; 2013 Jun; 40(6):831-41. PubMed ID: 23588942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
